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INTRODUCTION
The burden of human Immunodeficiency Virus (HIV)
infection in Nigeria is the second highest world-wide
with a challenge to the public health.1 The prevalence
of the disease is high among adolescents in sub-Saharan
African countries.2,3 In them, the disease might have
been contacted from birth, or via unprotected sexual
intercourse, use of contaminated blood products and
practice of  sharing sharp objects.4,5,6,7
HIV-infection is a risk factor for hearing loss and the
magnitude seems to increase with the severity of the
disease.8 This may be conductive or sensorineural. The
sensorineural hearing loss in HIV patients may be due
to direct neurotropic effect of HIV on either the central
nervous system or peripheral auditory nerve
(neurotoxicity).9,10,11 Sudden sensorineural hearing loss
and demyelination in the brain stem with significant
increase in latencies on auditory brain stem has been
reported 12, 13 and this may be due to the direct action
of  the virus on central nervous system. Other causes
of hearing loss in HIV infected adolescent may include
chronic suppurative otitis media, ototoxicity from
antiretroviral therapy and aminoglycosides used in the
treatment of tuberculosis which is a common
opportunistic infection that is associated with HIV. 8,14,15
Meningitis and encephalitis may occur as an
opportunistic infection in HIV patients because of poor
humoral and cell-mediated immunity, with a significant
consequence on hearing threshold.16 The defective
chemotaxis and phagocytosis may cause increased
vulnerability to middle ear infection17. The persistent
generalized lymphadenopathy could block the
Eustachian tube opening leading to serous otitis media
and conductive hearing loss.
The value of CD4 cell count measures the degree of
immunosuppression in HIV-positive patients. Highly
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Background: Human immunodeficiency virus-infected adolescents have
insufficient CD4 T cell count, and despite attaining viral suppression with HAART
regimen, some experience significant hearing loss.
Objective: To determine the association between the hearing thresholds in HIV-
positive adolescent on highly active antiretroviral therapy and CD4 T cell count.
Method: In this cross-sectional study, 63 adolescents receiving highly active
antiretroviral therapy had pure tone audiometry and hearing thresholds determined
using standard method. Additional data collected using proforma include bio-
data type of HAART regimens, treatment duration, the nadir and current CD4-
cell count (cells/ml) and viral load (copies/ml) levels. These clinical parameters
were correlated with hearing thresholds. Statistical analysis done included
univariate analysis and multivariate logistic regression using Statistical Product
and Service Solutions (SPSS version 20) and level of  statistical significance was
determined at P < 0.05.
Results: There were 63 participants comprising of 26 (41.3%) males and 37 (58.7%)
females, age ranged from 13 – 17 years (mean age 14.7years ± 1.65).  Hearing loss
was found in 20.6% adolescents and was predominantly sensorineural hearing
loss. There was asoociation between hearing threshold, nadir CD4 count and viral
load, but not with gender, current CD4 count and viral load, HAART regimen, and
treatment duration.
Conclusion: The high prevalence of  adolescents with hearing impairment showed
that there might be an association with the disease and/its treatment hence the
need for inclusion of periodic hearing evaluation in the routine clincal care of
HIV-infected adolescent on HAART.
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active antiretroviral therapy (HAART) often leads to
substantial reduction in viral load and immune recovery
in HIV-infected individual.18 CD4 T-cell status is a
strong prognostic indicator of mortality and disease
progression among individuals living with HIV.19
Some antiretroviral medications may be ototoxic20, thus
it has been difficult to make conclusions regarding the
cause of  changes in hearing function in HIV-infected
patients on the medication.
Accelerated aging has been suggested as a potential
explanation for the disproportionate increase in
complications of age related problems including
hearing loss even in individuals living with HIV/AIDS.
Improved medical, nutritional, psychosocial and
pharmacological care have converted HIV infection
from a terminal to a chronic health condition with
increased life expectancy8, thus making them to need
long-term hearing care.
Information is sparse on hearing status of  HIV-
infected adolescents in Nigeria, hence this study was
conducted to determine hearing threshold and the
association between it and viral load, CD4 cell counts
and HAART administration.
MATERIALS AND METHODS
This was a cross sectional study of  HIV-infected
adolescents at President’s Emergency Plan For AIDS
Relief  (PEPFAR) clinic, University College Hospital,
Ibadan, Nigeria. Ethical approval was obtained from
the ethics committee of University of Ibadan/
University College Hospital, Ibadan for the conduct
of  the study. Participants with clinical history suggestive
of risk factors for hearing loss were excluded from
the study. Permission was also obtained from the
management of  the clinic, and Informed consent was
obtained from their caregivers and assent was obtained
from each participant. A convenient sampling method
was done to recruit the participants.
Proforma was used to gather information/data on
sex, age, tribe, religion, duration of HIV infection,
sources of infection, use of HAART medications, ear
symptoms, history of  hearing impairment, and family
history of  hearing loss. Clinical and otoscopic
examination of  the ear was performed and findings
documented. Those with ear-wax and debris had
removal done before hearing test was performed.
Pure Tone Audiometry
The procedure was clearly explained to the patients.
In a quiet room, patients sat backing the equipment
and signified hearing the tone by raising hand above
the head level. Pure tones were delivered to each ear
consecutively using ear phones to test for air-conduction
(AC). The duration of  presentation was 2-3 seconds.
The test was conducted firstly on the right ear at 250Hz,
500Hz, 1KHz, 2KHz, 4KHz, 6KHz and 8KHz. The
test started by presenting pure tone at 40dBHL, if
audible then was reduced in 10dB steps till no response
occurred, thereafter it was increased by 5dB steps till
a response occurred and the result plotted. If no
response occurred at 80dBHL, then it was increased
by 5dB steps until a response occurred. The left ear
was then tested in similar manner. A pure tone average
was calculated at the speech frequencies 500Hz to 4
KHz. To test for bone conduction (BC), the bone
vibrator was placed on the mastoid of the test ear
(the worse ear on AC) delivering different tones at
each of the speech frequencies from 500Hz to 4000Hz.
Sensorineural hearing loss (SNHL) was diagnosed
when the air and bone conduction thresholds on
audiogram were within 10dB of each other and
thresholds were higher than 25dBHL. Mixed hearing
loss (MHL) was diagnosed when the air conduction
thresholds were poorer than bone conduction
thresholds by more than 10dB, and bone conduction
thresholds were less than 25dB.
Conductive hearing loss (CHL) was diagnosed if the
bone conduction thresholds were less than 25dB while
the air conduction thresholds are higher than 25dB.
In this study, hearing was said to be normal if  hearing
threshold is less than 26 dB HL. Hearing impairment
was classified as Mild (26 to 40 dB HL), Moderate
(41 to 55 dB HL), Moderately severe (56 to 70 dBHL),
Severe (71 to 90 dB HL), Profound (91 dBHL and
above).21
In this study, disabling hearing loss is defined as
permanent unaided hearing threshold level in the better
ear of 31 dB or greater” in the better hearing ear for
participants under the age of 15 years and 40dB or
greater in older people.22
Statistical analysis: Data collected were inputted into
Statistical Products and Service Solutions (IBMSPSS
version 20). Data analysis was done by univariate
analysis and multivariate logistic regression where
applicable. Some results were presented in tables and
charts where appropriate. The mean and standard
deviations were computed for all quantitative variables.
Level of statistical significance was set at P < 0.05.
RESULT
There were 63 participants comprising of 26 (41.3%)
males and 37 (58.7%) females. Their ages ranged from
13 – 17 years. Thirty-two (50.8%) belonged to the
low socioeconomic class, 18(28.8%) belonged to the.
middle socioeconomic class and 13 (20.6%) belonged
to the high socioeconomic class. All the participants
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were on daily dosage of co-trimoxazole and highly
active antiretroviral therapy (HAART) with 41 (65.1%)
participants on Lamivudine+Zidovudine+ Nevirapine
and 22 (34.9%) participants on Lamivudine
+Zidovudine+Efavirez. The period of HAART usage
ranged from 10 months to 9 years (mean of 6.9 ±
3.7years). There was no association between duration
of HAART usage and the degree of hearing loss
(p=0.81) as shown in Table 1. Hearing loss in the better
ear was found in 13 (20.6%) participants, which was
mild in 12 (92.3%) participants and moderate in one
participant. The type of hearing loss was sensorineural
hearing loss in 11 (84.6 %) and mixed hearing loss in 1
(7.7%) participant.
Of the participants with hearing loss, 8 (61.5%) had
disabling hearing loss. The hearing loss has no
association with age (p = 0.2). Hearing loss occurred
among patients treated with each of the HAART
regimens, but there is no association between hearing
loss and the HAART - regimen, after excluding the
confounding factors like age, gender and duration of
usage of the HAART (p = 0.11). The Nadir viral load
of the participants ranged from 29,653 - 76,983
copies/ml, mean of 54,711 ± 11,876 copies/ml while
latest viral load ranged from 201 – 4,500 copies/ml,
mean of 413 ± 287 copies/ml. The hearing thresholds
is associated with nadir viral load (p= 0.03), but not
the latest viral load (p = 0.18).
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Table1: Demographic and laboratory parameters of  the participants
Note:   Regimen I: Lamimudine+Zidovudine+Nevirapine;
Regimen II: Lamivudine+Zidovudine+Efavirez







Gender Male 5(38.4%) 3(23.1%) 8(61.5%)




(26 to 40 dB HL)
7(53.8%) 5(38.5%) 12 (92.3%))
Moderate hearing loss




Sensorineural Hearing Loss 6(46.1%) 5(38.5%) 11 (84.6 %)
Mixed Hearing Loss 1(7.7%) 0(0%) 1(7.7%)
Conductive Hearing Loss 1(7.7%) 0(0%) 1(7.7%)
Table 2: Hearing threshold of  the participants
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The Nadir CD4 cell count of the participants ranged
from 227 – 365 cells/mm3, mean of 301.83 ± 28.11
cells/mm 3 while the latest CD4 cell count ranged
from 487 cells /mm3 to 1,264 cells/mm3, mean 512
± 101 cells/mm3. The hearing threshold is associated
with the nadir CD4 cell count (p = 0.03), but not with
latest CD4 cell count (p = 0.35) as shown in table 2.
Multiple logistic regressions showed that nadir viral
load and nadir CD4 cell count could be associated
with hearing loss.
DISCUSSION
The participants’ age falls within the age group of
adolescents with HIV- infection in the previous
reports.23 The prevalence of  hearing impairment in this
study is higher than the prevalence of hearing loss
among children in the general population24, and lower
than the prevalence of 38.8% among HIV infected
children in Peru.25 This difference may be due to
environmental factors, viral load and CD4 cell count
status of  the participants.
Although, conductive HL is the principal type of
hearing loss in HIV infection,15,16,26 sensorineural hearing
loss was predominant in this study. The direct effect
of  HIV virus on the central nervous system or
peripheral auditory nerve might have contributed.26
The low incidence of conductive hearing loss in our
study may be because none of the participants had
history of ear discharge.26  This difference may also be
due to age of children investigated as this present study
only investigated the hearing of  adolescents. Studies
have shown the cause
of conductive hearing loss in HIV infected to be
Eustachian tube dysfunction and depressed cell
mediated immunity, which markedly increase
susceptibility to middle ear infection.27 The Eustachian
tube dysfunction in HIV adolescents may be due to
nasopharyngeal lymphoid hyperplasia, sinusitis, allergies
and their associated mucosal changes that results in
obstruction of the Eustachian tube and impairs the
middle ear ventilation.28
Torre et al 29 reported HIV as a factor for hearing loss,
and the magnitude of hearing loss seems to increase
with the severity of  HIV. The association of  hearing
loss with the nadir viral load and CD4 count in this
study supports the notion that high level of HIV virus
and low CD4 count may contribute to worsening
hearing. Although, mild hearing loss was found in
majority of the adolescent, this has been reported to
affect school performance and social interaction. In
this study, there was no relationship between hearing
loss and HAART. Early initiation of  antiretroviral
therapy may prevent hearing loss as there are no
consensus that antiretroviral medications could affect
hearing. If  care of  these hearing impaired adolescent
is neglected, it could affect their communication, social
and educational development, with significant
consequences on the communities and the country.30
Hearing loss increased with increasing age among the
participants, though not statistically significant, probably
because the participants were within the same age
bracket. The observed none association between
hearing thresholds, and latest CD4 cell count and viral
load of the participants supports the neurotoxic
aetiopathogenesis effect of HIV on the auditory
system. The introduction of the HAART reduced the
viral load and improved their CD4 cell counts as shown
in Table 1. Low CD4 count has been reportedly
associated with neural degeneration in HIV-infected
individuals.31
Limitation of this study is that it is a cross sectional
study, the audiological profile were not monitored
routinely in the clinic while patients were on the HARRT
regimen
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